A5054029390- Neurological disorders and treatments
- Parkinson's Disease Mechanisms and Treatments
- Genetic Neurodegenerative Diseases
- Neuroscience and Neural Engineering
- Acute Ischemic Stroke Management
- Neuroscience and Neuropharmacology Research
- Cerebral Venous Sinus Thrombosis
- Photochromic and Fluorescence Chemistry
- Transcranial Magnetic Stimulation Studies
- Photoreceptor and optogenetics research
- Botulinum Toxin and Related Neurological Disorders
- Neuroscience and Music Perception
- Gastrointestinal motility and disorders
- EEG and Brain-Computer Interfaces
- Neural dynamics and brain function
- Dysphagia Assessment and Management
- Nuclear Receptors and Signaling
- Intraocular Surgery and Lenses
- Sleep and Wakefulness Research
- Temporomandibular Joint Disorders
- Intracerebral and Subarachnoid Hemorrhage Research
- Cognitive Functions and Memory
- Trigeminal Neuralgia and Treatments
- Glycogen Storage Diseases and Myoclonus
- Restless Legs Syndrome Research
University of Florida
2025
Juntendo University
2017-2024
John Wiley & Sons (United States)
2024
Juntendo University Hospital
2018-2022
Ijinkai Takeda General Hospital
1992
Pembrolizumab is an immune-checkpoints inhibitor that enhances the immune response against cancer cells and therefore useful for treatment of several carcinomas. However, pembrolizumab sometimes perturbs system resulting in various autoimmune neurological complications. In this situation, myositis due to a rare but not-negligible complication. Here, we report two cases pembrolizumab, with systemic involving levator palpebrae superioris, extraocular hindneck muscles.Case 1 was 78-year-old man...
DBS Think Tank IX was held on August 25–27, 2021 in Orlando FL with US based participants largely person and overseas joining by video conferencing technology. The founded 2012 provides an open platform where clinicians, engineers researchers (from industry academia) can freely discuss current emerging deep brain stimulation (DBS) technologies as well the logistical ethical issues facing field. consensus among speakers that expanded its scope has been applied to multiple disorders effort...
IntroductionApproaches for objectively measuring facial expressions and speech may enhance clinical research evaluation in telemedicine, which is widely employed Parkinson's disease (PD). This study aimed to assess the feasibility efficacy of using an artificial intelligence-based chatbot improve smile PD. Further, we explored potential predictive value objective face parameters motor symptoms, cognition, mood.MethodsIn this open-label randomized study, collected a series conversational...
Abstract Continuous, objective monitoring of motor signs and symptoms may help improve tracking disease progression treatment response in Parkinson’s (PD). This study assessed the analytical clinical validity multi-sensor smartwatch measurements hospitalized home-based settings (96 patients with PD; mean wear time 19 h/day) using a twice-daily virtual examination (VME) at times representing medication OFF/ON states. Digital measurement performance was better during inpatient assessments for...
Background Parkinson’s disease (PD) is a progressive neurodegenerative condition that primarily affects motor functions; it caused by the loss of midbrain dopaminergic (mDA) neurons. The therapeutic effects transplanting human-induced pluripotent stem cell (iPSC)-derived mDA neural progenitor cells in animal PD models are known and being evaluated an ongoing clinical trial. However, improvements safety efficiency differentiation-inducing methods crucial for providing larger scale therapy...
Abstract Background Chronic constipation is a common digestive complication of Parkinson's disease (PD). Objectives To verify the usefulness elobixibat, an ileal bile acid transporter inhibitor, for chronic in PD. Methods This double‐blind, placebo‐controlled study consisted 2‐week observation/washout period and 4‐week treatment period. All patients received Bowel Movement Diary at Week ‐2 were allocated to elobixibat (10 mg) or placebo 0. Patients visited Weeks 2 4 report daily spontaneous...
In the advanced stages of Parkinson's disease (PD), motor complications such as wearing-off and dyskinesia are problematic vary daily. These symptoms need to be monitored precisely provide adequate care for patients with PD.
BackgroundDeep brain stimulation (DBS) of the subthalamic nucleus (STN) has been widely performed for medically refractory Parkinson's disease (PD). Recent new technology multiple independent current control (MICC) with directional lead provides both vertical and horizontal steering on purposes. Consequently, MICC allows fine adjustment tailoring condition individual patient. It is also expected to avoid induced adverse effects.MethodsWe retrospectively investigated situation reason doing so...
Introduction Chronic constipation worsens the quality of life (QOL) patients with Parkinson’s disease (PD). Elobixibat, an ileal bile acid transporter inhibitor, is a useful laxative, but its effect on chronic in PD remains unclear. Therefore, we designed placebo-controlled, randomised, double-blind study to investigate efficacy and safety elobixibat constipation. Methods analysis The will consist 2-week observation 4-week treatment periods. Patients clinically established record status...
Holmes tremor (HT) is a refractory associated with cortico-basal ganglia loops and cerebellothalamic tract abnormalities. Various drug treatments have been attempted; however, no treatment method has yet established. Historically, thalamic deep brain stimulation (DBS) performed in medically cases. Recently, the posterior subthalamic area (PSA) used for HT. Here, we report cases of HT review effectiveness safety PSA-DBS HT.We conducted retrospective chart two patients who underwent PSA-DBS....
Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is a common therapeutic option for advanced Parkinson's disease (PD). STN-DBS could improve symptoms sporadic PD; however, reports on familial PD are limited. The coiled-coil-helix-coiled-coil-helix domain containing 2 (CHCHD2) was identified as possible pathogenicity middle-aged onset with autosomal dominant inheritance.1 Herein, we present case bilateral in patient harboring CHCHD2 p.T61I mutation family independent original...
Sense of time (temporal sense) is believed to be processed by various brain regions in a complex manner, among which the basal ganglia, including striatum and subthalamic nucleus (STN), play central roles. However, precise mechanism for processing sense has not been clarified. To examine role STN temporal directly manipulating function switching deep stimulation (DBS) device On/Off 28 patients with Parkinson’s disease undergoing STN-DBS therapy. The test session was performed approximately...
Abstract Levodopa‐induced dyskinesia (LID) is a common complication in patients with advanced Parkinson's disease (PD) undergoing treatment levodopa. Glutamate receptor antagonists can suppress LID; however, the underlying mechanisms remain unclear. Here, we aimed to evaluate effect of 3‐((2‐methyl‐1,3‐thiazol‐4‐yl)ethynyl)pyridine (MTEP), metabotropic glutamate 5 (mGluR5) antagonist, on dyskinesia. We recorded neuronal activity entopeduncular nucleus and examined responses cortical electric...
Acquired hepatocerebral degeneration (AHD) is a syndrome that causes progressive cognitive decline, psychiatric symptoms, movement disorders, and myelopathy in approximately 1% of chronic hepatic dysfunction cases. Movement disorders occur about 60% all patients with AHD ataxia, parkinsonism, chorea, dystonia.1 Parkinsonism typically symmetric, early gait disturbance, predominant postural/action tremors, often globus pallidum (GP) hyperintensity on T1-weighted images (T1-WI) but varying...